Valneva SE (VALN) , a specialty vaccine company, recently reported positive Phase 3 - VLA1553-321 data in adolescents (12 to 17 years old) for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ. For investors’ note, IXCHIQ is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need. The trial data supports and strengthens the pivotal data previously reported for adolescents in the United States, Europe and Canada. Data from this trial are also e ...